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Available online 6 February 2008Early diabetic retinopathy is characterized by changes in subtle visual functions such as contrast
sensitivity and dark adaptation. The outcome of several studies suggests that glutamate is
involved in retinal neurodegeneration during diabetes. We hypothesized that the protein levels
of ionotropic glutamate receptor subunits are altered in the retina during diabetes. Therefore,we
investigated whether human diabetic patients have altered immunoreactivity of ionotropic
glutamate receptor subunits in the retina. In total, 12 donor eyes from subjects with diabetes
mellitus were examined and compared to 6 eyes from non-diabetic subjects without known
ocular disease, serving as controls. Immunohistochemical analysiswasperformedusing specific
antibodies directed against the ionotropic α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate
(AMPA) receptor subunits GluR1, GluR2, GluR4, and against theN-methyl-D-aspartate glutamate
receptor subunit NR1. In the inner plexiformandouter plexiform layers the immunoreactivity of
GluR2 andNR1 subunitswas significantly increased in subjectswith diabeteswhen compared to
the levels found in controls. No significant changes in GluR1 and GluR4 subunit expressionwere
observed.
These results suggest that early visual dysfunction in diabetic patients may be due, at
least partially, to changes in glutamate receptor subunit expression or distribution.
© 2007 Elsevier B.V. All rights reserved.Keywords:
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Ionotropic glutamate receptors1. Introduction
Diabetic retinopathy (DR) is a leading cause of blindness in
working-ageadults indevelopedcountries. Thevascular changeslogy of Coimbra, IBILI, Fa
. Ambrósio).
er B.V. All rights reservedthat occur in DR are well documented, and include loss of
pericytes and endothelial cells, the formation of microaneu-
rysms, basementmembrane thickeningandblood-retinal barrier
breakdown (Cai and Boulton, 2002). In addition to the vascularculty of Medicine, Celas, 3000-548 Coimbra, Portugal. Fax: +351 239
.
154 B R A I N R E S E A R C H 1 1 9 8 ( 2 0 0 8 ) 1 5 3 – 1 5 9alterations, changes in the neural retina during diabetes have
also been reported (Abu El-Asrar et al., 2007; Barber, 2003; Lieth
etal., 2000), and thesealterationsmayaccount for loss in contrast
sensitivity and color vision and for alterations in the electro-
retinogram (Roy et al., 1986; Sokol et al., 1985).
The initiatingmechanisms bywhich diabetes causes vision
loss are still not clearly understood, but the excitatory neuro-
transmitter glutamate has been implicated. It was shown that
both themetabolismand the concentration of glutamate in the
retina are altered after short-term experimental diabetes.
Diabetic rat retinas are less able to convert glutamate into
glutamine (Lieth et al., 1998) and the concentration of glu-
tamate in the retina of streptozotocin (STZ)-induced diabetic
rats is increased (Kowluru et al., 2001). Also, glutamate levels
are increased in the vitreous of patients with proliferative DR
(Ambati et al., 1997), suggesting increased levels in the retina.
Moreover, the high-affinity L-glutamate/L-aspartate transpor-
ter (GLAST) is impaired in retinal Müller cells isolated from
STZ-induced diabetic rats, probably due to oxidation of the
glutamate transporter (Li and Puro, 2002).
Glutamate receptors are divided into two major classes of
receptors: ionotropic andmetabotropic. The ionotropicglutamate
receptors are further subdivided into three groups: α-amino-3-
hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), kainate
(KA) and N-methyl-D-aspartate (NMDA) receptors. While the
metabotropic receptors are single polypeptides linked to
G-proteins, the ionotropic receptors are multimeric complexes,
with AMPA receptors being assembled from subunits designated
GluR1–4; kainate receptors from subunits GluR5–7, KA1, andKA2;
andNMDAreceptors fromNR1,NR2A–D, andNR3Asubunits. The
ion channels associated with NMDA receptors are highly perme-
able to Ca2+, whereas AMPA and kainate receptor-associated
channels are usually less permeable to Ca2+. However, certain
combinations of subunits increase the Ca2+-permeability ofFig. 1 – GluR1 subunit immunoreactivity in control (upper panel
retinas. All pictures were obtained with identical exposure time
representative images. The densitometric measurements were p
values over the selected area are expressed in percentage of con
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layAMPA and kainate receptor-linked channels. For example,
AMPA receptors lacking the GluR2 subunit are Ca2+-permeable
(Jensen et al., 1998; Oguro et al., 1999).
Glutamate is the major excitatory neurotransmitter in the
central nervous system, including the retina (Ozawaetal., 1998).
Photoreceptors, bipolar cells and ganglion cells release gluta-
mate tomediate the transfer of visual signals from the retina to
the brain. In the mammalian retina, ionotropic glutamate
receptor subunits have been shown to have a widespread and
differential distribution throughout the retina (Brandstatter and
Hack, 2001; Brandstatter et al., 1998; Thoreson and Witkovsky,
1999; Yang, 2004).
Unregulated glutamate levels are a potential causal factor in
a variety of central nervous system disorders (Cull-Candy et al.,
2001; Osborne andHerrera, 1994; Sucher et al., 1991). In addition
to altered glutamate levels, changes in the distribution and
functional characteristics of glutamate receptorsmay also alter
glutamate neurotransmission in the retina during diabetes. In
fact, previously, we have showed that ionotropic glutamate
receptor subunit expression is changed in cultured retinal
neural cells exposed to elevated glucose concentration (San-
tiago et al., 2006), and Ng et al. reported the upregulation of NR1
and GluR2/3 subunits in ganglion, amacrine and bipolar cells as
well as in the inner and outer plexiform layers in the retina of
four and 16 weeks diabetic rats (Ng et al., 2004).
In this work, we investigated whether diabetes changes the
protein expression levels of ionotropic glutamate receptor
subunits in the human retina.2. Results
The effect of diabetes on the protein expression of ionotropic
glutamate receptorsubunitswasanalyzed inhumanpostmortem, open bars) and diabetic (lower panel, black bars) human
s for control and diabetic retinas, and the pictures shown are
erformed using ImageJ software, and the average pixel gray
trol. Abbreviations: ONL, outer nuclear layer; OPL, outer
er; GCL, ganglion cell layer. Bar: 20 µm.
Fig. 2 – GluR2 subunit immunoreactivity in control (upper panel, open bars) and diabetic (lower panel, black bars) human
retinas. All pictures were obtained with identical exposure times for control and diabetic retinas, and the pictures shown are
representative images. The densitometric measurements were performed using ImageJ software, and the average pixel gray
values over the selected area are expressed in percentage of control. Abbreviations: ONL, outer nuclear layer; OPL, outer
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. *p<0.05, significantly different from
control; two-tailed Student's t-test. Bar: 20 µm.
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agebetweencontrolsanddiabeticpatients (72±4years incontrols
and 68±3 years in diabetic patients), neither in the postmortem
time toenucleation (7.5±0.6h incontrolsand6.5±1.1h indiabetic
patients) (Table 1).
The protein expression pattern of ionotropic glutamate
receptor subunits in the retina of mammals has been docu-
mented before (Brandstatter, 2002; Brandstatter and Hack,
2001; Brandstatter et al., 1998; Hamassaki-Britto et al., 1993;Fig. 3 – GluR4 subunit immunoreactivity in control (upper panel
retinas. All pictures were obtained with identical exposure times
representative images. The densitometric measurements were p
values over the selected area are expressed in percentage of con
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layMuller et al., 1992; Peng et al., 1995). The presentation of
results will therefore focus primarily on diabetes-associated
alterations. Densitometric analysis for the immunoreactivity
of each antibody used was performed in the IPL and OPL.
2.1. GluR1 subunit
The distribution of immunoreactivity of GluR1 subunit in
control and diabetic human retinas is shown in Fig. 1. GluR1, open bars) and diabetic (lower panel, black bars) human
for control and diabetic retinas, and the pictures shown are
erformed using ImageJ software, and the average pixel gray
trol. Abbreviations: ONL, outer nuclear layer; OPL, outer
er; GCL, ganglion cell layer. Bar: 20 µm.
Fig. 4 – NR1 subunit immunoreactivity in control (upper panel, open bars) and diabetic (lower panel, black bars) human retinas.
All pictures were obtained with identical exposure times for control and diabetic retinas, and the pictures shown are
representative images. The densitometric measurements were performed using ImageJ software, and the average pixel gray
values over the selected area are expressed in percentage of control. Abbreviations: ONL, outer nuclear layer; OPL, outer
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. *p<0.05, significantly different from
control; two-tailed Student's t-test. Bar: 20 µm.
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and in INL, ONL and GCL. Immunoreactivity in control and
diabetic retinas did not differ significantly.
2.2. GluR2 subunit
In control retinas, most of the GluR2 subunit immunoreactivi-
ty was observed in OPL (Fig. 2). Weaker immunoreactivity was
found in IPL. The GCLwas almost devoid of immunoreactivity.
In diabetic retinas, GluR2 subunit immunoreactivity in-
creased in OPL, as compared to the controls, and a strong
immunoreactivity was found in IPL with a punctuate appear-
ance, homogenously distributed. Stronger immunoreactivity
was also observed in GCL in diabetic human retinas.
Densitometric analysis of the GluR2 subunit immunoreactivi-
ty in OPL and IPL confirmed the increase in immunoreactivity in
both layers indiabetic retinas. In IPL, immunoreactivity increased
to 222±37% (p<0.05) and in the OPL to 188±26% (p<0.05), com-
pared to control group.
2.3. GluR4 subunit
The GluR4 subunit distribution was more restricted than that
of the other AMPA glutamate receptor subunits. Immunor-
eactivity of GluR4 subunit (Fig. 3) was confined to the plexi-
form layers, more to the OPL. The immunoreactivity patterns
observed in the IPL and OPL did not change in diabetic patients
compared to controls.
2.4. NR1 subunit
In control retinas, most of the NR1 subunit immunoreactivity
was observed in GCL (Fig. 4). A moderate level of immunore-
activity was also observed in IPL.In diabetic retinas, NR1 subunit immunoreactivity was
found in all retinal layers. The intensity of the immunore-
activity was noticeably increased, particularly in the GCL.
Densitometric analysis showed a significant increase in NR1
subunit immunoreactivity to 258±53% (p<0.05) and 227±31%
(p<0.05) of the control in IPL and OPL, respectively.3. Discussion
The main purpose of this study was to investigate whether
diabetes changes the expression of ionotropic glutamate re-
ceptor subunits in the human retina. Our results show that
diabetic human retinas without manifest signs of DR have
increased immunostaining of GluR2 and NR1 subunits, indica-
ting elevated tissue levels of these proteins. We did not find
detectable changes in the immunoreactivity of GluR1 andGluR4
subunits in human diabetic patients.
AMPA receptors are important mediators of fast excitatory
neurotransmission in the retina. AMPA receptors are less
permeable to calcium than NMDA receptors. However, AMPA
receptors lacking the GluR2 subunit have increased calcium
permeability (Jensen et al., 1998; Kondo et al., 2000; Oguro et al.,
1999). In general, the expression pattern of the different glu-
tamate receptor subunits is in linewith thepatternsdescribed in
mammals by others (Brandstatter, 2002; Brandstatter and Hack,
2001; Brandstatter et al., 1998; Hamassaki-Britto et al., 1993;
Muller et al., 1992; Peng et al., 1995). In contrast to their findings,
we observed immunoreactivity for GluR1 subunit in the ONL,
suggesting that some axons and cell bodies of photoreceptors
contain GluR1 subunits. A similar result, in goldfish retina, was
previously reported (Vandenbranden et al., 2000).
The increase in the protein levels of GluR2 subunit in the
retina of diabetic rats is in accordance with several other
Table 1 – Subjects characteristics
Case # Age Sex Type of
diabetes
Cause of
death
Death to
enucleation
time (h)
Control subjects
192 75 M Heart disease 7
203 79 M Heart disease 10
232 75 M CVA 8
444 68 M Heart disease 6
450 79 M Heart disease 8
740 54 M Heart disease 6
Diabetic subjects
277 78 M DM2 (NID) CVA 4
288 70 M DM1 Heart disease 15
321 78 M DM2 (ID) Heart disease 11
335 68 F DM1 Heart disease 7
342 69 M DM1 CVA 5
346 63 M DM2 (ID) Heart disease 2
430 77 F DM1 Heart disease 1
479 47 M DM1 Other 9
626 66 F DM2 (NID) Heart disease 5
692 66 M DM1 Heart disease 7
730 77 F DM2 (ID) Heart disease 5
738 58 M DM2 (ID) Heart disease 7
DM1 = type 1 diabetes; DM2 = type 2 diabetes; NID = non-insulin-
dependent; ID= insulin-dependent; CVA=cerebral vascular accident;
Heart disease = coronary artery disease, heart failure or heart
arrhythmias.
Table 2 – Primary antibodies used in this study
Primary antibody Dilution Sourcea
Rabbit anti-GluR1 1:100 Chemicon International
Goat anti-GluR2 1:750 Santa Cruz Biotechnology, Inc.
Rabbit anti-GluR4 1:750 Chemicon International
Rabbit anti-NR1 1:100 Chemicon International
a Location: Chemicon International, Temecula, CA, USA; Santa
Cruz Biotechnology, Santa Cruz, CA, USA.
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GluR2 subunit expression is also increased in high glucose-trea-
ted rat retinal cells and that calcium homeostasis is deregulated
(Santiago et al., 2006). Ng et al. (2004) have shown an increase in
GluR2/3 subunit expression in ganglion, amacrine and bipolar
cells aswell as in the inner and outer plexiform layers in one and
four weeks STZ-induced diabetic rats. In addition, the ob/ob
mouse, a model of type 2 diabetes, was found to have increased
binding sites for AMPA andNMDA receptors in the graymatter of
the spinal cord (Li et al., 1999). In the brain of STZ-diabetic rats the
binding properties of AMPA receptors and the expression of
NMDA receptor subunits were also altered (Di Luca et al., 1999;
Gagne et al., 1997). The functional implications of the higher
content of the GluR2 subunit in diabetic subjects are not yet clear
but it may be speculated that it will decrease the Ca2+-per-
meability of AMPA receptor-associated channels.
Ourobservationson increasedNR1subunit immunoreactivi-
ty in the diabetic human retina are in accordance with previous
findings in diabetic rats (Ng et al., 2004). The NMDA receptor
channels provide an important route for Ca2+ entry, and subse-
quent activation of Ca2+-dependent intracellular enzymes. Neu-
rotoxicity associated with excitatory amino acids was reported
to bemediated to a large extent through the activation of NMDA
receptors (Romano et al., 1995; Vorwerk et al., 1996). In the
context of diabetes, the increase of NR1 subunit expression and
of retinal glutamate content may therefore contribute to the
retinal neuronal loss observed in diabetes (Aizu et al., 2002;
Barber et al., 2005, 1998; Martin et al., 2004; Park et al., 2003;
Santiago et al., 2007). However, within the complex regulation of
glutamatesignalingandmetabolismin the retina, severalmecha-
nisms may counteract the damaging effect brought upon byincreased NR1 levels. Desensitization of the glutamate-mediated
response is an important physiological property of the AMPA
receptors, and the upregulation of GluR2may be a compensatory
response to limit the possible damage caused by excessive glu-
tamate levels (Jayakar and Dikshit, 2004). Previously, it was
already reported that the increase of NR1 subunit protein level is
accompanied by an increase in the levels of the calcium-binding
proteins, calbindin and parvalbumin (Ng et al., 2004). These
proteins function as buffer in order to maintain the calcium ho-
meostasis and to protect cells against the potentially damaging
effects of excessive calcium influx during overexcitatory activity.
In conclusion, the observed changes in ionotropic glutamate
receptor subunit expression show that diabetes changes amain
component of excitatory neurotransmission, suggesting a
potential impairment of synaptic communication throughout
the retina,whichmaycontribute toeventual color visiondefects
or loss of contrast sensitivity.4. Experimental procedures
4.1. Retinal tissue
Donor eyes were obtained and used in the study in accordance
with the provisions of the Declaration of Helsinki for research
involvinghuman tissue. Humandonor eyes, rejected for corneal
transplantation because of corneal opacities or abnormalities of
corneal endothelium, were obtained from the Cornea Bank,
Amsterdam. No donor details were revealed, other than sex,
age, postmortem timeand cause ofdeath. In total, 12donor eyes
from subjects with diabetes mellitus but without manifest
diabetic retinopathy, according to ophthalmological examina-
tion, and 6 eyes from non-diabetic subjects without known
ocular disease serving as control subjects were examined.
Details about the donors are given in Table 1.
4.2. Immunohistochemistry
Intact eyes were snap frozen in liquid nitrogen cooled in iso-
pentane and stored at −80 °C until used. Tissue blocks of the
posterior half of the frozen human globes were cut starting at
the base of the optic nerve, extending anteriorly to the mid-
periphery of the eye using a sterile razor blade. Serial cryostat
sections (10 µm thick) of both control and diabetic patientswere
placed on the same slide in order to minimize methodological
variation during immunostaining. Sections were air dried and
fixed in 2% paraformaldehyde in 0.1 M phosphate buffer (PB; pH
7.0) for 10min at room temperature and then rinsed with PB for
30min. Sectionswere then incubated for 1 h in 0.05MPB (pH7.0)
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1% bovine serum albumin, at room temperature. Sections were
subsequently incubatedovernightwithprimary antibody (listed
inTable2) diluted in0.05MPBcontaining 3%NGS, 0.4%TritonX-
100, and 1% BSA, at room temperature. Negative controls were
included, by omitting the primary antibody, but these never
yielded immunoreactivity patterns.
Sections were incubated with the secondary antibodies for
1 h in 1% NGS at room temperature. Immunoreactivity was
visualized using indocarbocyanine (Cy3)-conjugated affinity-
purified F(ab′)2 secondary antibodies, either goat anti-rabbit,
or rabbit anti-goat IgG (1:600; Jackson Immuno Research;
Brunschwig Chemie, Amsterdam, The Netherlands). Sections
were washed and coverslipped in Vectashield mounting
medium with DAPI (Vector Laboratories, Amsterdam, The
Netherlands). The preparations were visualized with a micro-
scope (Axioshop 2 Plus; Carl Zeiss Meditec, Inc.), coupled to a
camera (Axiocam HRc; Carl Zeiss Meditec., Inc.). Microscope
settings and exposure times were kept identical for all the
control and diabetic retinas to obtain an accurate representation
of the differences in immunoreactivity intensities. Adobe Photo-
shop was used to scale and arrange the TIFF files for presenta-
tion. Densitometric analysis was performed using the public
domain ImageJ program (http://rsb.info.nih.gov/ij/) in the plexi-
form layers, OPL and IPL, because these are the regions where
the glutamatergic synapses are located, and, in addition, these
layers can be more easily defined for quantification purposes.
4.3. Statistical analysis
From each subject, 3 sections were stained and at least 3
images were randomly acquired from each section. For each
image, the backgroundmean gray value was obtained from the
biggest region possible without cells and was subtracted from
the mean gray value obtained for each retinal layer analyzed.
Results are presented as mean±SEM. Statistical analysis
was performed using the two-tailed Student's t-test.Acknowledgments
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